Sulbactam‐durlobactam: A novel β‐lactam‐β‐lactamase inhibitor combination targeting carbapenem‐resistant Acinetobacter baumannii infections
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023-06 · 43 (6) · 502-513
DOI: 10.1002/phar.2802 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, online erschienen am 23.05.2023. Verfasst von Amer El-Ghali und 4 weiteren Autor:innen. Beteiligte Einrichtung: Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University…. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Acinetobacter Infections. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Carbapenem‐resistant Acinetobacter baumannii (CRAB) is a difficult‐to‐treat nosocomial pathogen responsible for significant morbidity and mortality. Sulbactam‐durlobactam (SUL‐DUR), formerly ETX2514SUL, is a novel β‐lactam‐β‐lactamase inhibitor designed specifically for the treatment of CRAB infections. The United States Food and Drug Administration (FDA) fast‐track approval of SUL‐DUR for the treatment of CRAB infections is currently pending after completion of the phase III ATTACK trial, which compared SUL‐DUR to colistin, both in combination with imipenem‐cilastatin (IMI) for patients with CRAB‐associated hospital‐acquired bacterial pneumonia, ventilator‐associated pneumonia, and bacteremia. The results of this trial demonstrated that SUL‐DUR was non‐inferior to colistin for CRAB while also possessing a much more favorable safety profile. SUL‐DUR was well‐tolerated with the most common side effects being headache, nausea, and injection‐site phlebitis. With the current landscape of limited effective treatment options for CRAB infections, SUL‐DUR represents a promising therapeutic option for the treatment of these severe infections. This review will discuss the pharmacology, spectrum of activity, pharmacokinetics/pharmacodynamics, in vitro and clinical studies, safety, dosing, administration, as well as the potential role in therapy for SUL‐DUR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
- Department of Pharmacy Services, Detroit Receiving Hospital, Detroit Medical Center, Detroit, Michigan, USA.
- Division of Infectious Diseases, Department of Medicine, Wayne State University, Detroit, Michigan, USA.
ORCID-Profile: Amer El-Ghali, Ashlan J Kunz Coyne, Kaylee Caniff, Michael J Rybak
Zitieren
APA
El-Ghali, A., Kunz Coyne, A. J., Caniff, K., Bleick, C., & Rybak, M. J. (2023). Sulbactam‐durlobactam: A novel β‐lactam‐β‐lactamase inhibitor combination targeting carbapenem‐resistant Acinetobacter baumannii infections. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 43(6), 502-513. https://doi.org/10.1002/phar.2802
Vancouver
El-Ghali A, Kunz Coyne AJ, Caniff K, Bleick C, Rybak MJ. Sulbactam‐durlobactam: A novel β‐lactam‐β‐lactamase inhibitor combination targeting carbapenem‐resistant Acinetobacter baumannii infections. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023;43(6):502-513. doi:10.1002/phar.2802
BibTeX
@article{ElGhali2023,
author = {El-Ghali, Amer and Kunz Coyne, Ashlan J and Caniff, Kaylee and Bleick, Callan and Rybak, Michael J},
title = {Sulbactam‐durlobactam: A novel β‐lactam‐β‐lactamase inhibitor combination targeting carbapenem‐resistant Acinetobacter baumannii infections},
journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
year = {2023},
volume = {43},
number = {6},
pages = {502--513},
doi = {10.1002/phar.2802}
}
EUVIMED